The influence of different combinations of cardiometabolic risk factors on the prevalence of MASLD and risk of advanced fibrosis deserves attention

AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease

(2023) Mary E. Rinella et al.   HEPATOLOGY

Changing from NAFLD through MAFLD to MASLD: Similar prevalence and risk factors in a large Brazilian cohort

(2023) Hugo Perazzo et al.   JOURNAL OF HEPATOLOGY

Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease?

(2022) Zobair M. Younossi et al.   HEPATOLOGY

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

(2020) Mohammed Eslam et al.   JOURNAL OF HEPATOLOGY

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

(2017) Thomas Karlas et al.   JOURNAL OF HEPATOLOGY

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

(2015) Mattias Ekstedt et al.   HEPATOLOGY